Manhattan Isotope Technology (MIT), a subsidiary of PET developer Positron, has signed an agreement with the Institute for Nuclear Research (INR) of Troitsk, Russia, to collaborate on the production of strontium-82 (Sr-82).
The goal is to increase the annual production capability for Sr-82 at the institute and bolster supply of the radioisotope to key markets, Positron said.
Initial shipments of Sr-82 samples are expected to arrive at the MIT facility in Lubbock, TX, in the spring of 2012. The samples will be processed at MIT for final purification into an active pharmaceutical ingredient, which will undergo validation next year.
